Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Sarepta Therapeutics (SRPT)

Sarepta Therapeutics names Michael Severino CEO, effective July 28, 2026, succeeding Doug Ingram

Neutral Impact 4 of 5 leadership Written later

Sarepta Therapeutics appointed Michael Severino, M.D., former CEO of Tessera Therapeutics, as chief executive officer effective July 28, 2026, and as a Class I director. Doug Ingram, the current CEO, departs as CEO and board member on that date and will serve as a consultant until December 31, 2026. The filing describes a sign-on equity package with a grant date value of approximately $35 million and a base salary of $1,180,000, which shareholders may track for compensation and leadership continuity.

Key points

  • Michael Severino, M.D., becomes CEO and a director effective July 28, 2026, succeeding Doug Ingram
  • Sign-on equity grant has an approximate grant date value of $35,000,000, including a $14,000,000 make-whole grant
  • Severino's employment agreement sets an annual base salary of $1,180,000 and a target bonus of 110% of base salary
  • Ingram will consult for the company until December 31, 2026, for a monthly fee of $15,000

The filing

CompanySarepta Therapeutics (SRPT)
Form8-K, current report
Filed with the SECJul 27, 2026, 9:08 AM ET
Accession number0001193125-26-316995

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.